The stock of Tourmaline Bio Inc (TRML) has seen a 32.31% increase in the past week, with a -2.85% drop in the past month, and a -7.62% decrease in the past quarter. The volatility ratio for the week is 10.10%, and the volatility levels for the past 30 days are at 8.24% for TRML. The simple moving average for the past 20 days is 9.30% for TRML’s stock, with a -15.84% simple moving average for the past 200 days.
Is It Worth Investing in Tourmaline Bio Inc (NASDAQ: TRML) Right Now?
Company’s 36-month beta value is 2.09.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRML is 16.04M, and currently, short sellers hold a 20.12% ratio of that floaft. The average trading volume of TRML on April 18, 2025 was 337.52K shares.
TRML) stock’s latest price update
The stock price of Tourmaline Bio Inc (NASDAQ: TRML) has surged by 10.26 when compared to previous closing price of 14.52, but the company has seen a 32.31% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-13 that – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M.
Analysts’ Opinion of TRML
Many brokerage firms have already submitted their reports for TRML stocks, with Wedbush repeating the rating for TRML by listing it as a “Outperform.” The predicted price for TRML in the upcoming period, according to Wedbush is $42 based on the research report published on March 06, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see TRML reach a price target of $50. The rating they have provided for TRML stocks is “Outperform” according to the report published on December 06th, 2024.
H.C. Wainwright gave a rating of “Buy” to TRML, setting the target price at $49 in the report published on November 11th of the previous year.
TRML Trading at 10.99% from the 50-Day Moving Average
After a stumble in the market that brought TRML to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.25% of loss for the given period.
Volatility was left at 8.24%, however, over the last 30 days, the volatility rate increased by 10.10%, as shares sank -5.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.19% upper at present.
During the last 5 trading sessions, TRML rose by +32.31%, which changed the moving average for the period of 200-days by +25.67% in comparison to the 20-day moving average, which settled at $14.65. In addition, Tourmaline Bio Inc saw -21.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRML starting from Kulkarni Sandeep Chidambar, who purchase 1,779 shares at the price of $14.85 back on Aug 21 ’24. After this action, Kulkarni Sandeep Chidambar now owns 7,000 shares of Tourmaline Bio Inc, valued at $26,418 using the latest closing price.
Kulkarni Sandeep Chidambar, the CEO of Tourmaline Bio Inc, purchase 5,221 shares at $13.79 during a trade that took place back on Aug 16 ’24, which means that Kulkarni Sandeep Chidambar is holding 5,221 shares at $71,998 based on the most recent closing price.
Stock Fundamentals for TRML
Current profitability levels for the company are sitting at:
- -2243.3 for the present operating margin
The net margin for Tourmaline Bio Inc stands at -1830.25. The total capital return value is set at -0.3. Equity return is now at value -28.99, with -28.20 for asset returns.
Based on Tourmaline Bio Inc (TRML), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -316.65.
Currently, EBITDA for the company is -89.73 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 9524.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 40.33.
Conclusion
In a nutshell, Tourmaline Bio Inc (TRML) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
